Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) therapies after its drug candidate pimicotinib cleared a phase 3 tr
Two years ago, Merck KgAA was talking up xevinapant as a leap forward in head and neck cancer and one of the brightest stars in its late-stage pipeline, Now, the drug has been abandoned aft
Germany’s Merck KGaA has agreed to acquire Mirus Bio, a specialist in transfection reagents used in the production of cell and gene therapies (CGTs), in a deal valued at a
Mere months after announcing a partnership to develop digital support tools for cancer patients, Huma Therapeutics and Merck KGaA have launched their first app in the UK.
Germany’s Merck KGaA has partnered with techbio company Caris Discovery in a $1.4 billion alliance that will apply artificial intelligence to the design of antibody-drug c
Germany’s Merck KGaA is paying $45 million upfront for rights to a potentially first-in-class drug for colorectal cancer (CRC) being developed by New York biotech Inspirna